Should we incorporate ablative radiotherapy in standard treatment of advanced intrahepatic cholangiocarcinoma?

Cholangiocarcinoma still remains a rare neoplasm, but the great and rapid increase in incidence, especially of the intrahepatic form probably caused by exposure to unsuspected but extremely widespread risk factors as asbestos (1), makes it necessary that every oncologist acquires the appropriate knowledge for management of cholangiocarcinoma, a challenging disease in the oncology landscape. As the diagnostic and therapeutic pathway for cholangiocarcinoma can be declined in different modalities, patients should early referred to a multidisciplinary team in tertiary center where all diagnostic and therapeutic tools are available and where there’s familiarity with patients management algorithm (2). A recent study by Tao and colleagues (3) suggests that a powerful new weapon can be helpful in the management of intrahepatic cholangiocarcinoma (IHCC).